Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients

Prostate Cancer and Prostatic Diseases

Volumn 7, Issue 4, 2004, Pages 350-354

  Rodrigues, Paulo ^a,b   Hering, F ^a   Campagnari, J C ^a  

^a HOSPITAL BENEFICÊNCIA PORTUGUESA DE SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Bisphosphonates; Bone metastasis; Pain palliation; Prostate carcinoma; Prostate metastasis

Indexed keywords

ANALGESIC AGENT; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; CYPROTERONE ACETATE; ESTRAMUSTINE PHOSPHATE; ESTROGEN; GONADORELIN DERIVATIVE; HORMONE; KETOCONAZOLE; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; CANCER PAIN; CANCER RELAPSE; CANCER RESISTANCE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DRUG EFFICACY; DRUG USE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHLEBITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; STUDENT T TEST; VISUAL ANALOG SCALE; BONE TUMOR; METASTASIS; MIDDLE AGED; NEOPLASM; PAIN; PAIN ASSESSMENT; PALLIATIVE THERAPY; PATHOLOGY; PROSTATE TUMOR; TIME;

AGED; AGED, 80 AND OVER; ANALGESICS, NON-NARCOTIC; BONE NEOPLASMS; CLODRONIC ACID; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 16644363491     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500752     Document Type: Article

References (22)

1. Berruti A et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164: 1248-1253.
2. Greenlee RT, Murray T, Bolden S. Cancer statistics, 2000. American Cancer Society, January/February 2000; 50: 6-11.
3. Parker SL, Tong T, Bolden S. Cancer statistics 1997. Cancer J Clin 1997; 47: 5-6.
4. Issacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26: 263-269.
5. Smith Jr JA, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology 1999; 54: 8-12.
6. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19: 18-54.
7. Dodwell DJ. Malignant bone resorption: Cellular and biochemical mechanisms. Ann oncol 1992; 3: 257-267.
8. Powles T et al. Controled trial of clodronate in patient with primary operable breast cancer. J Clin Oncol 2002; 20: 3219-3224.
9. Orr F, Lee J, Duivenvoorden WC. Pathophysiologic interactions in skeletal metastasis. Cancer, Suppl 2000; 88: 2912-2915.
10. Sansoni P, Passeri G, Fangnoni F. Inhibition of antigen presenting and cell function by alendronate in vitro. J. Bone Miner Res 1995; 10: 1719-1723.
11. Lissoni P, Cazzanigna M, Barni, Derenne S. Acute effect of pamidronate administration on serum levels of interleukin-6 in advanced solid tumor patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2. Eur J Cancer 1992; 33: 304-308.
12. Diel IJ, Solomayer EF, Costa SD. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-363.
13. Luckman SP, Huges DE, Loxon FF. Nitrogen containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins including Ras. J Bone Miner Res 1998; 13: 581-589.
14. Adami S, Salvagno G, Guarrera G. Dichloromethylene - biphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 1985; 134: 1152-1155.
15. Vorreuther R. Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Br J Urol 1993; 72: 792-795.
16. Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001; 165: 136-140.
17. Dearnaley DP et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003; 95: 1300-1311.
18. Munoy GR. Bisphosphonates and tumor burden. J Clin Oncol 2002; 20: 3191-3192.
19. Smith Jr JA. Palliation of painful bone metastases from prostate cancer using sodium etidronate: Results of randomized, prospective, double-blind placebo controlled study. J Urol 1989; 141: 85-87.
20. Jagdev SP et al. Comparison of effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption with metastatic bone disease. Ann Oncol 2001; 12: 1433-1438.
21. Ernst DS et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/predinisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003; 21: 3335-3342.
22. Saad F et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.